Scalper1 News
Biotech Sarepta Therapeutics (SRPT) revealed more data from its latest trial of muscular-dystrophy drug eteplirsen Thursday morning, sending the stock up sharply in early trading. Sarepta said that after three years on eteplirsen, the subjects of its phase-two study of Duchenne muscular dystrophy (DMD) in a six-minute walk test showed an advantage of 151 meters compared with the control group. The control group here was somewhat non-standard, Scalper1 News
Scalper1 News